Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' Morton, DL' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 142 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Wood, TF; DiFronzo, LA; Rose, DM; Haigh, PL; Stern, SL; Wanek, L; Essner, R; Morton, DL
      Does complete, resection of melanoma metastatic to solid intra-abdominal organs improve survival?

      ANNALS OF SURGICAL ONCOLOGY
    2. Habal, N; Gupta, RK; Bilchik, AJ; Yee, R; Leopoldo, Z; Ye, W; Elashoff, RM; Morton, DL
      CancerVax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer

      ANNALS OF SURGICAL ONCOLOGY
    3. Tsioulias, GJ; Gupta, RK; Tisman, G; Hsueh, EC; Essner, R; Wanek, LA; Morton, DL
      Serum TA90 antigen-antibody complex as a surrogate marker for the efficacyof a polyvalent allogeneic whole-cell vaccine (CancerVax) in melanoma

      ANNALS OF SURGICAL ONCOLOGY
    4. Wood, TF; Saha, S; Morton, DL; Tsioulias, GJ; Rangel, D; Hutchinson, W; Foshag, LJ; Bilchik, AJ
      Validation of lymphatic mapping in colorectal cancer: In vivo, ex vivo, and laparoscopic techniques

      ANNALS OF SURGICAL ONCOLOGY
    5. Wood, TF; Spirt, M; Rangel, D; Shen, P; Tsioulias, GJ; Morton, DL; Bilchik, AJ
      Lymphatic mapping improves staging during laparoscopic colectomy for cancer

      SURGICAL ENDOSCOPY-ULTRASOUND AND INTERVENTIONAL TECHNIQUES
    6. Cochran, AJ; Morton, DL; Stern, S; Lana, AMA; Essner, R; Wen, DR
      Sentinel lymph nodes show profound downregulation of antigen-presenting cells of the paracortex: Implications for tumor biology and treatment

      MODERN PATHOLOGY
    7. Bilchik, AJ; Saha, S; Wiese, D; Stonecypher, JA; Wood, TF; Sostrin, S; Turner, RR; Wang, HJ; Morton, DL; Hoon, DSB
      Molecular staging of early colon cancer on the basis of sentinel node analysis: A multicenter phase II trial

      JOURNAL OF CLINICAL ONCOLOGY
    8. Kelley, MC; Gupta, RK; Hsueh, EC; Yee, R; Stern, S; Morton, DL
      Tumor-associated antigen TA90 immune complex assay predicts recurrence andsurvival after surgical treatment of stage I-III melanoma

      JOURNAL OF CLINICAL ONCOLOGY
    9. Balch, CM; Buzaid, AC; Soong, SJ; Atkins, MB; Cascinelli, N; Coit, DG; Fleming, ID; Gershenwald, JE; Houghton, A; Kirkwood, JM; McMasters, KM; Mihm, MF; Morton, DL; Reintgen, DS; Ross, MI; Sober, A; Thompson, JA; Thompson, JF
      Final version of the American Joint Committee on Cancer staging system forcutaneous melanoma

      JOURNAL OF CLINICAL ONCOLOGY
    10. Morton, DL
      Cytoreductive surgery and adjuvant immunotherapy in the management of metastatic melanoma

      TUMORI
    11. Habal, N; Giuliano, AE; Morton, DL
      The use of sentinel lymphadenectomy to identify candidates for postoperative adjuvant therapy of melanoma and breast cancer

      SEMINARS IN ONCOLOGY
    12. Taback, B; Fujiwara, Y; Wang, HJ; Foshag, LJ; Morton, DL; Hoon, DSB
      Prognostic significance of circulating microsatellite markers in the plasma of melanoma patients

      CANCER RESEARCH
    13. Haigh, PI; Lucci, A; Turner, RR; Bostick, PJ; Krasne, DL; Stern, SL; Morton, DL
      Carbon dye histologically confirms the identity of sentinel lymph nodes incutaneous melanoma

      CANCER
    14. DiFronzo, LA; Wanek, LA; Morton, DL
      Earlier diagnosis sf second primary melanoma confirms the benefits of patient education and routine postoperative follow-up

      CANCER
    15. Ravindranath, MH; Gonzales, A; Soh, D; Nishimoto, K; Tam, WY; Bilchik, A; Morton, DL; O'Day, S
      Interleukin-2 binds to ganglioside GD(1b)

      BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
    16. Rose, DM; Essner, R; Hughes, TMD; Tang, PCY; Bilchik, A; Wanek, LA; Thompson, JF; Morton, DL
      Surgical resection for metastatic melanoma to the liver - The John Wayne Cancer Institute and Sydney Melanoma Unit Experience

      ARCHIVES OF SURGERY
    17. Broelsch, C; Brennan, MF; Niederhuber, JE; Wanebo, HJ; Morton, DL
      Results of hepatic resection for sarcoma metastatic to liver - Discussion

      ANNALS OF SURGERY
    18. Nakayama, T; Taback, B; Turner, R; Morton, DL; Hoon, DSB
      Molecular clonality of in-transit melanoma metastasis

      AMERICAN JOURNAL OF PATHOLOGY
    19. Shen, P; Conforti, AM; Essner, R; Cochran, AJ; Turner, RR; Morton, DL
      Is the node of Cloquet the sentinel node for the iliac/obturator node group?

      CANCER JOURNAL
    20. Balch, CM; Morton, DL
      Second-time surgery for stage IV sarcoma (A model of sequential metastases)

      JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
    21. Chan, AD; Essner, R; Wanek, LA; Morton, DL
      Judging the therapeutic value of lymph node dissections for melanaoma

      JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
    22. Chan, AD; Essner, R; Wanek, LA; Morton, DL
      Judging the therapeutic value of lymph node dissections for melanaoma - Reply

      JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
    23. Shen, P; Wanek, LA; Morton, DL
      Is adjuvant radiotherapy necessary after positive lymph node dissection inhead and neck melanomas?

      ANNALS OF SURGICAL ONCOLOGY
    24. Habal, N; Gupta, RK; Bilchik, AJ; Johnson, T; Morton, DL
      TA90-IC, a new marker for advanced colon cancer

      ANNALS OF SURGICAL ONCOLOGY
    25. Hsueh, EC; Gupta, RK; Yee, R; Leopoldo, ZC; Qi, K; Morton, DL
      Does endogenous immune response determine the outcome of surgical therapy for metastatic melanoma?

      ANNALS OF SURGICAL ONCOLOGY
    26. Shen, P; Guenther, JM; Wanek, LA; Morton, DL
      Can elective lymph node dissection decrease the frequency and mortality rate of late melanoma recurrences?

      ANNALS OF SURGICAL ONCOLOGY
    27. Ravindranath, MH; Shen, P; Habal, N; Soh, D; Nishimoto, K; Gonzales, A; Tam, WY; Bilchik, A; Morton, DL
      Does human melanoma express carcinoembryonic antigen?

      ANTICANCER RESEARCH
    28. Cochran, AJ; Elashoff, D; Morton, DL; Elashoff, R
      Individualized prognosis for melanoma patients

      HUMAN PATHOLOGY
    29. Essner, R; Bostick, PJ; Glass, EC; Foshag, LJ; Haigh, PI; Wang, HJ; Morton, DL
      Standardized probe-directed sentinel node dissection in melanoma

      SURGERY
    30. Essner, R; Huynh, Y; Nguyen, T; Morton, DL; Hoon, DSB
      Functional interleukin 4 receptor and interleukin 2 receptor common gamma-chain on human non-small cell lung cancers: Novel targets for immune therapy

      JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
    31. Hoon, DSB; Bostick, P; Kuo, C; Okamoto, T; Wang, HJ; Elashoff, R; Morton, DL
      Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence

      CANCER RESEARCH
    32. Cochran, AJ; Balda, BR; Starz, H; Bachter, D; Krag, DN; Cruse, CW; Pijpers, R; Morton, DL
      The Augsburg consensus - Techniques of lymphatic mapping, sentinel lymphadenectomy, and completion lymphadenectomy in cutaneous malignancies

      CANCER
    33. Chu, KU; Ravindranath, NH; Gonzales, A; Nishimoto, K; Tam, WY; Soh, D; Bilchik, A; Katopodis, N; Morton, DL
      Gangliosides as targets for immunotherapy for pancreatic Adenocarcinoma

      CANCER
    34. Balch, CM; Buzaid, AC; Atkins, MB; Cascinelli, N; Coit, DG; Fleming, ID; Houghton, A; Kirkwood, JM; Mihm, MF; Morton, DL; Reintgen, D; Ross, MI; Sober, A; Soong, SJ; Thompson, JA; Thompson, JF; Gershenwald, JE; McMasters, KM
      A new American Joint Committee on Cancer staging system for cutaneous melanoma

      CANCER
    35. Tsioulias, GJ; Wood, TF; Morton, DL; Bilchik, AJ
      Lymphatic mapping and focused analysis of sentinel lymph nodes upstage gastrointestinal neoplasms

      ARCHIVES OF SURGERY
    36. Bilchik, AJ; Wood, TF; Allegra, D; Tsioulias, GJ; Chung, M; Rose, DM; Ramming, KP; Morton, DL
      Cryosurgical ablation and radiofrequency ablation for unresectable hepaticmalignant neoplasms - A proposed algorithm

      ARCHIVES OF SURGERY
    37. Wood, TF; Tsioulias, GJ; Morton, DL; Rangel, D; Hutchinson, W; Foshag, LJ; Turner, RR; Bilchik, AJ
      Focused examination of sentinel lymph nodes upstages early colorectal carcinoma

      AMERICAN SURGEON
    38. Morton, DL; Chan, AD
      The concept of sentinel node localization: How it started

      SEMINARS IN NUCLEAR MEDICINE
    39. Essner, R; Stern, S; Bostick, P; Morton, DL
      Results of lymphatic mapping in melanoma

      LYMPHATIC MAPPING AND PROBE APPLICATIONS IN ONCOLOGY
    40. Cochran, AJ; Wen, DR; Morton, DL
      Surgical pathology of dye-directed selective lymph node dissection

      LYMPHATIC MAPPING AND PROBE APPLICATIONS IN ONCOLOGY
    41. Bilchik, AJ; Rose, DM; Allegra, DP; Bostick, PJ; Hsueh, E; Morton, DL
      Radiofrequency ablation: A minimally invasive technique with multiple applications

      CANCER JOURNAL FROM SCIENTIFIC AMERICAN
    42. Kelemen, PR; Essner, R; Foshag, LJ; Morton, DL
      Lymphatic mapping and sentinel lymphadenectomy after wide local excision of primary melanoma

      JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
    43. Morton, DL; Chan, AD
      Current status of intraoperative lymphatic mapping and sentinel lymphadenectomy for melanoma: Is it standard of care?

      JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
    44. Haigh, PI; Essner, R; Wardlaw, JC; Stern, SL; Morton, DL
      Long-term survival after complete resection of melanoma metastatic to the adrenal gland

      ANNALS OF SURGICAL ONCOLOGY
    45. DiFronzo, LA; Wanek, LA; Elashoff, R; Morton, DL
      Increased incidence of second primary melanoma in patients with a previouscutaneous melanoma

      ANNALS OF SURGICAL ONCOLOGY
    46. Essner, R; Conforti, A; Kelley, MC; Wanek, L; Stern, S; Glass, E; Morton, DL
      Efficacy of lymphatic mapping, sentinel lymphadenectomy, and selective complete lymph node dissection as a therapeutic procedure for early-stage melanoma

      ANNALS OF SURGICAL ONCOLOGY
    47. Morton, DL; Bostick, PJ
      Will the true sentinel node please stand? Reply

      ANNALS OF SURGICAL ONCOLOGY
    48. Kelemen, PR; Wanek, LA; Morton, DL
      Lymph node biopsy does not impair survival after therapeutic dissection for palpable melanoma metastases

      ANNALS OF SURGICAL ONCOLOGY
    49. Ollila, DW; Foshag, LJ; Essner, R; Stern, SL; Morton, DL
      Parotid region lymphatic mapping and sentinel lymphadenectomy for cutaneous melanoma

      ANNALS OF SURGICAL ONCOLOGY
    50. Morton, DL; Bostick, PJ
      Will the true sentinel node please stand?

      ANNALS OF SURGICAL ONCOLOGY
    51. O'Day, SJ; Gammon, G; Boasberg, PD; Martin, MA; Kristedja, TS; Guo, M; Stern, S; Edwards, S; Fournier, P; Weisberg, M; Cannon, M; Fawzy, NW; Johnson, TD; Essner, R; Foshag, LJ; Morton, DL
      Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma

      JOURNAL OF CLINICAL ONCOLOGY
    52. Bostick, PJ; Morton, DL; Turner, RR; Huynh, KT; Wang, HJ; Elashoff, R; Essner, R; Hoon, DSB
      Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients

      JOURNAL OF CLINICAL ONCOLOGY
    53. Lavine, SD; Petrovich, Z; Cohen-Gadol, AA; Masri, LS; Morton, DL; O'Day, SJ; Essner, R; Zelman, V; Yu, C; Luxton, G; Apuzzo, MLJ
      Gamma knife radiosurgery for metastatic melanoma: An analysis of survival,outcome, and complications

      NEUROSURGERY
    54. Morton, DL; Ollila, DW
      Critical review of the sentinel node hypothesis

      SURGERY
    55. Lucci, A; Turner, RR; Morton, DL
      Carbon dye as an adjunct to isosulfan blue dye for sentinel lymph node dissection

      SURGERY
    56. Ollila, DW; Hsueh, EC; Stern, SL; Morton, DL
      Metastasectomy for recurrent stage IV melanoma

      JOURNAL OF SURGICAL ONCOLOGY
    57. Ollila, DW; Morton, DL
      Tumor doubling time and survival

      JOURNAL OF SURGICAL ONCOLOGY
    58. Takahashi, T; Johnson, TD; Nishinaka, Y; Morton, DL; Irie, RF
      IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlatewith survival of melanoma patients

      JOURNAL OF INVESTIGATIVE DERMATOLOGY
    59. Fujiwara, Y; Chi, DDJ; Wang, HJ; Keleman, P; Morton, DL; Turner, R; Hoon, DSB
      Plasma DNA microsatellites as tumor-specific markers and indicators of tumor progression in melanoma patients

      CANCER RESEARCH
    60. Hsueh, EC; Lucci, A; Qi, K; Morton, DL
      Survival of patients with melanoma of the lower extremity decreases with distance from the trunk

      CANCER
    61. Hsueh, EC; Nathanson, L; Foshag, LJ; Essner, R; Nizze, JA; Stern, SL; Morton, DL
      Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases

      CANCER
    62. Morton, DL; Ollila, DW; Hsueh, EC; Essner, R; Gupta, RK
      Cytoreductive surgery and adjuvant immunotherapy: A new management paradigm for metastatic melanoma

      CA-A CANCER JOURNAL FOR CLINICIANS
    63. Morton, DL; Thompson, JF; Essner, R; Elashoff, R; Stern, SL; Nieweg, OE; Roses, DF; Karakousis, CP; Mozzillo, N; Reintgen, D; Wang, HJ; Glass, EC; Cochran, AJ
      Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma - A multicenter trial

      ANNALS OF SURGERY
    64. Balch, CM; Morton, DL; Bland, KI; Wanebo, HJ
      Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: A multicenter trial - Discussion

      ANNALS OF SURGERY
    65. KELLEY MC; OLLILA DW; MORTON DL
      LYMPHATIC MAPPING AND SENTINEL LYMPHADENECTOMY FOR MELANOMA

      Seminars in surgical oncology
    66. OLLILA DW; KELLEY MC; GAMMON G; MORTON DL
      OVERVIEW OF MELANOMA VACCINES - ACTIVE SPECIFIC IMMUNOTHERAPY FOR MELANOMA PATIENTS

      Seminars in surgical oncology
    67. Bilchik, AJ; Giuliano, A; Essner, R; Bostick, P; Kelemen, P; Foshag, LJ; Sostrin, S; Turner, RR; Morton, DL
      Universal application of intraoperative lymphatic mapping and sentinel lymphadenectomy in solid neoplasms

      CANCER JOURNAL FROM SCIENTIFIC AMERICAN
    68. KUO CT; BOSTICK PJ; IRIE RF; MORTON DL; CONRAD AJ; HOON DSB
      ASSESSMENT OF MESSENGER-RNA OF BETA-1-]4-N-ACETYLGALACTOSAMINYLTRANSFERASE AS A MOLECULAR MARKER FOR METASTATIC MELANOMAL

      Clinical cancer research
    69. KUO CT; BOSTICK PJ; IRIE RF; MORTON DL; CONRAD AJ; HOON DSB
      ASSESSMENT OF MESSENGER-RNA OF BETA-1-]4-N-ACETYLGALACTOSAMINYLTRANSFERASE AS A MOLECULAR MARKER FOR METASTATIC MELANOMAL

      Clinical cancer research
    70. MORTON DL
      MINIMALLY INVASIVE STAGING OF PATIENTS WITH MELANOMA - SENTINEL LYMPHADENECTOMY AND DETECTION OF THE MELANOMA-SPECIFIC PROTEINS MART-1 AND TYROSINASE BY REVERSE-TRANSCRIPTASE POLYMERASE-CHAIN-REACTION - INVITED COMMENTARY

      Journal of the American College of Surgeons
    71. HSUEH EC; GUPTA RK; GLASS EC; YEE R; QI K; MORTON DL
      POSITRON-EMISSION-TOMOGRAPHY PLUS SERUM TA90 IMMUNE-COMPLEX ASSAY FORDETECTION OF OCCULT METASTATIC MELANOMA

      Journal of the American College of Surgeons
    72. HSUEH EC; FAMATIGA E; GUPTA RK; QI K; MORTON DL
      ENHANCEMENT OF COMPLEMENT-DEPENDENT CYTOTOXICITY BY POLYVALENT MELANOMA CELL VACCINE (CANCERVAX) - CORRELATION WITH SURVIVAL

      Annals of surgical oncology
    73. DABROWSKA DM; ELASHOFF RM; HO W; MORTON DL
      IDENTIFYING PREDICTIVE FACTORS IN MELANOMA PROGRESSION

      Oncology Reports
    74. COCHRAN AJ; ELASHOFF D; MORTON DL; ELASHOFF R
      INDIVIDUALIZED PROGNOSIS FOR MELANOMA PATIENTS

      Modern pathology
    75. HSUEH EC; GUPTA RK; QI K; MORTON DL
      CORRELATION OF SPECIFIC IMMUNE-RESPONSES WITH SURVIVAL IN MELANOMA PATIENTS WITH DISTANT METASTASES RECEIVING POLYVALENT MELANOMA CELL VACCINE

      Journal of clinical oncology
    76. HOON DSB; OKAMOTO T; WANG HJ; ELASHOFF R; NIZZE AJ; FOSHAG LJ; GAMMON G; MORTON DL
      IS THE SURVIVAL OF MELANOMA PATIENTS RECEIVING POLYVALENT MELANOMA CELL VACCINE LINKED TO THE HUMAN-LEUKOCYTE ANTIGEN PHENOTYPE OF PATIENTS

      Journal of clinical oncology
    77. TAKAHASHI T; CONFORTI A; KIKUMOTO Y; HOON DSB; MORTON DL; IRIE RF
      AUGMENTATION OF IGM ANTIBODY TO GP43 TUMOR-ASSOCIATED ANTIGEN PEPTIDEBY MELANOMA CELL VACCINE

      Journal of clinical immunology
    78. LUCCI A; CHO WI; HAN TY; GIULIANO AE; MORTON DL; CABOT MC
      GLUCOSYLCERAMIDE - A MARKER FOR MULTIPLE-DRUG RESISTANT CANCERS

      Anticancer research
    79. GLASS EC; ESSNER R; MORTON DL
      KINETICS OF 3 LYMPHOSCINTIGRAPHIC AGENTS IN PATIENTS WITH CUTANEOUS MELANOMA

      The Journal of nuclear medicine
    80. Chan, AD; Morton, DL
      Active immunotherapy with allogeneic tumor cell vaccines: Present status

      SEMINARS IN ONCOLOGY
    81. Ollila, DW; Stern, SL; Morton, DL
      Tumor doubling time: A selection factor for pulmonary resection of metastatic melanoma

      JOURNAL OF SURGICAL ONCOLOGY
    82. HUANG SKS; OKAMOTO T; MORTON DL; HOON DSB
      ANTIBODY-RESPONSES TO MELANOMA MELANOCYTE AUTOANTIGENS IN MELANOMA PATIENTS/

      Journal of investigative dermatology
    83. Okamoto, T; Irie, RF; Fujii, S; Huang, SKS; Nizze, AJ; Morton, DL; Hoon, DSB
      Anti-tyrosinase-related protein-2 immune response in vitiligo patients andmelanoma patients receiving active-specific immunotherapy

      JOURNAL OF INVESTIGATIVE DERMATOLOGY
    84. RAVINDRANATH MH; KELLEY MC; JONES RC; AMIRI AA; BAUER PM; MORTON DL
      RATIO OF IGG - IGM ANTIBODIES TO SIALYL LEWIS(X) AND GM(3) CORRELATESWITH TUMOR-GROWTH AFTER IMMUNIZATION WITH MELANOMA-CELL VACCINE WITH DIFFERENT ADJUVANTS IN MICE

      International journal of cancer
    85. KELLEY MC; JONES RC; GUPTA RK; YEE R; STERN S; WANEK L; MORTON DL
      TUMOR-ASSOCIATED ANTIGEN TA-90 IMMUNE-COMPLEX ASSAY PREDICTS SUBCLINICAL METASTASIS AND SURVIVAL FOR PATIENTS WITH EARLY-STAGE MELANOMA

      Cancer
    86. MOORE FD; ROSENBERG SA; FOLKMAN JM; MORTON DL; BALCH CM; SPENCER FC
      DURABILITY OF COMPLETE RESPONSES IN PATIENTS WITH METASTATIC CANCER TREATED WITH HIGH-DOSE INTERLEUKIN-2 - IDENTIFICATION OF THE ANTIGENS MEDIATING RESPONSE - DISCUSSION

      Annals of surgery
    87. MORTON DL
      INTRAOPERATIVE LYMPHATIC MAPPING AND SENTINEL LYMPHADENECTOMY - COMMUNITY STANDARD CARE OR CLINICAL INVESTIGATION

      The cancer journal from Scientific American
    88. HSUEH EC; GUPTA RK; QI K; YEE R; LEOPOLDO ZC; MORTON DL
      TA90 IMMUNE-COMPLEX PREDICTS SURVIVAL FOLLOWING SURGERY AND ADJUVANT VACCINE IMMUNOTHERAPY FOR STAGE-IV MELANOMA

      The cancer journal from Scientific American
    89. DALE PS; FOSHAG LJ; WANEK LA; MORTON DL
      METASTASIS OF PRIMARY MELANOMA TO 2 SEPARATE LYMPH-NODE BASINS - PROGNOSTIC-SIGNIFICANCE

      Annals of surgical oncology
    90. FARZAD Z; MCBRIDE WH; OGBECHI H; ASNONGHOLTHOFF C; MORTON DL; COCHRAN AJ
      LYMPHOCYTES FROM LYMPH-NODES AT DIFFERENT DISTANCES FROM HUMAN-MELANOMA VARY IN THEIR CAPACITY TO INHIBIT ENHANCE TUMOR-CELL GROWTH IN-VITRO/

      Melanoma research
    91. RAVINDRANATH MH; BAUER PM; AMIRI AA; MIRI SM; KELLEY MC; JONES RC; MORTON DL
      CELLULAR CANCER VACCINE INDUCES DELAYED-TYPE HYPERSENSITIVITY REACTION AND AUGMENTS ANTIBODY-RESPONSE TO TUMOR-ASSOCIATED CARBOHYDRATE ANTIGENS (SIALYL LE(A), SIALYL LE(X), GD(3) AND GM(2)) BETTER THAN SOLUBLELYSATE CANCER VACCINE

      Anti-cancer drugs
    92. RAVINDRANATH MH; MORTON DL
      IMMUNOGENICITY OF MEMBRANE-BOUND GANGLIOSIDES IN VIABLE WHOLE-CELL VACCINES

      Cancer investigation
    93. WEN DR; MORTON DL; COCHRAN AJ
      THE PATHOLOGY OF MELANOMA PATIENTS WITH NEGATIVE SENTINEL NODES WHO SUBSEQUENTLY DEVELOP IPSILATERAL NODAL METASTASES

      Laboratory investigation
    94. MORTON DL
      INTRODUCTION - SENTINEL LYMPHADENECTOMY FOR PATIENTS WITH CLINICAL STAGE-I MELANOMA

      Journal of surgical oncology
    95. CONFORTI AM; OLLILA DW; KELLEY MC; GAMMON G; MORTON DL
      UPDATE ON ACTIVE SPECIFIC IMMUNOTHERAPY WITH MELANOMA VACCINES

      Journal of surgical oncology
    96. TAKAHASHI T; IRIE RF; MORTON DL; HOON DSB
      RECOGNITION OF GP43 TUMOR-ASSOCIATED ANTIGEN PEPTIDE BY BOTH HLA-A2 RESTRICTED CTL LINES AND ANTIBODIES FROM MELANOMA PATIENTS

      Cellular immunology
    97. SARANTOU T; CHI DDJ; GARRISON DA; CONRAD AJ; SCHMID P; MORTON DL; HOON DSB
      MELANOMA-ASSOCIATED ANTIGENS AS MESSENGER-RNA DETECTION MARKERS FOR MELANOMA

      Cancer research
    98. RAVINDRANATH MH; AMIRI AA; BAUER PM; KELLEY MC; ESSNER R; MORTON DL
      ENDOTHELIAL-SELECTIN LIGANDS SIALYL LEWIS(X) AND SIALYL LEWIS(A) ARE DIFFERENTIATION ANTIGENS IMMUNOGENIC IN HUMAN-MELANOMA

      Cancer
    99. CHI DDJ; MERCHANT RE; RAND R; CONRAD AJ; GARRISON D; TURNER R; MORTON DL; HOON DSB
      MOLECULAR-DETECTION OF TUMOR-ASSOCIATED ANTIGENS SHARED BY HUMAN CUTANEOUS MELANOMAS AND GLIOMAS

      The American journal of pathology
    100. JONES RC; KELLEY M; GUPTA RK; NIZZE JA; YEE R; LEOPOLDO Z; QI K; STERN S; MORTON DL
      IMMUNE-RESPONSE TO POLYVALENT MELANOMA CELL VACCINE IN AJCC STAGE-IIIMELANOMA - AN IMMUNOLOGICAL SURVIVAL MODEL

      Annals of surgical oncology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/10/20 alle ore 01:06:55